Montreal Heart Institute in Canada has said that the COLCORONA clinical study, assessing colchicine, will continue enrolment of non-hospitalised adults with Covid-19.
The announcement is based on a recommendation from the independent data monitoring committee (DMC) following a futility analysis.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
COLCORONA is coordinated by the Montreal Health Innovations Coordinating Center (MHICC) with funding from the Government of Quebec, the Bill & Melinda Gates Foundation, and the US’ National Heart, Lung, and Blood Institute (NHLBI).
In addition, the trial is being conducted in collaboration with CGI and Pharmascience.
COLCORONA primary investigator Dr Jean-Claude Tardif said: “We are pleased to have achieved this important milestone and now await the final results of COLCORONA to determine the effect of colchicine in preventing complications in non-hospitalised patients with Covid-19.
“We are committed to including large number of patients worldwide in this robust study to determine the effect of colchicine on the serious inflammatory storm seen with Covid-19, potentially keeping patients out of the hospital and ultimately saving lives.”
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThe COLCORONA study is a contact-free, at-home, randomised, double-blind, placebo-controlled study being performed at several sites in Canada, the US, Europe, South America, and Africa.
It is designed to assess the ability of colchicine to prevent the major inflammatory storm that develops in adults with serious complications due to Covid-19. Participants must be aged 40 years and above.
The primary objective is to investigate if short-term treatment with the medication can decrease the rate of death and lung complications caused by Covid-19. Colchicine will be compared to placebo.
In May this year, the Canadian Center for Vaccinology (CCfV) at Dalhousie University obtained approval from Health Canada to conduct the country’s first clinical trials of a potential Covid-19 vaccine.
